Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Clive S. Zent, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Betsy R. LaPlant, Thomas E. Witzig, Stephen M. Ansell & George J. Weiner. (2015) Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leukemia & Lymphoma 56:8, pages 2373-2378.
Read now
Read now
Paolo Strati, Wei-Gang Tong, Candida Vitale, William G. Wierda, Susan O’Brien, Jennifer R. Brown, Wen-Kai Weng, Thomas Kipps, Michael J. Keating & Alessandra Ferrajoli. (2015) A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 56:6, pages 1878-1880.
Read now
Read now
Paolo Strati, Alessandra Ferrajoli, Susan Lerner, Susan O’Brien, William Wierda, Michael J. Keating & Stefan Faderl. (2014) Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 55:4, pages 828-833.
Read now
Read now
Daphne R. Friedman. (2013) “Primum non nocere”: the addition of granulocyte-macrophage colony stimulating factor to alemtuzumab in chronic lymphocytic leukemia. Leukemia & Lymphoma 54:3, pages 441-442.
Read now
Read now
Articles from other publishers (5)
Clive S. ZentXin Victoria Wang, Rhett P. Ketterling, Curtis A. Hanson, Edward N. Libby, Jacqueline C. Barrientos, Timothy G. Call, Julie E. Chang, Jane J. Liu, Alejandro R. Calvo, Hillard M. Lazarus, Jacob M. Rowe, Selina M. Luger, Mark R. Litzow & Martin S. Tallman. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). American Journal of Hematology 91:3, pages 308-312.
Crossref
Crossref
Jonathon B. Cohen, Silvana Bucur, Elliott F. Winton, Rajni Sinha, Leonard T. Heffner, Nassoma King, Sagar Lonial, Amelia A. Langston, Edmund K. Waller, Amanda Hutchison-Rzepka, Amanda Colbert, Mary Jo Lechowicz & Christopher R. Flowers. (2015) Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 15:9, pages 514-518.
Crossref
Crossref
Clive S. Zent, Ronald P. Taylor, Margaret A. Lindorfer, Paul V. Beum, Betsy LaPlant, Wenting Wu, Timothy G. Call, Deborah A. Bowen, Michael J. Conte, Lori A. Frederick, Brian K. Link, Sue E. Blackwell, Suresh Veeramani, Nisar A. Baig, David S. Viswanatha, George J. Weiner & Thomas E. Witzig. (2014) Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. American Journal of Hematology 89:7, pages 757-765.
Crossref
Crossref
Margaret Lindorfer, Paul Beum & Ronald Taylor. (2013) CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I. Antibodies 2:4, pages 598-616.
Crossref
Crossref
Lina Reslan & Charles Dumontet. 2013. Resistance to Immunotherapeutic Antibodies in Cancer. Resistance to Immunotherapeutic Antibodies in Cancer
1
24
.